LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITY

MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice Continue reading

LamdaGen Corporation receives Official Notice of Allowance from the Japanese Patent Office for issuance of patent: MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS

MENLO PARK, CA, January 8, 2021—  LamdaGen Corporation, a developer of  plasmonic  biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent application entitled MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS which enables high Continue reading

Introducing L’AuRa – the result of diligent discovery, state of the art nano-science and a collaborative team penchant for uncompromising precision

Technology Platform for Quantitative, Ultra-Sensitive and Rapid Diagnostics MENLO PARK, CA, October 26, 2016 – LamdaGen Corporation, a leading developer of diagnostic biosensors, introduced the L’AuRa digital platform to meet the requirements of decentralized, patient-centric mobile testing while delivering precision, Continue reading